Chronic graft versus host disease
- Chronic GVHD
News & Events
On this page
NCATS Co-Sponsored Conferences
American Society of Gene & Cell Therapy (ASGCT) 19th Annual Meeting, Wednesday, May 04, 2016 - Saturday, May 07, 2016
Location: Washington, DC
Description: Save the date and plan to head to Washington, DC on May 4-7, 2016, for the premiere gene and cell therapy conference in the world. Taking place at the Marriott Wardman Park Hotel, the ASGCT 19th Annual Meeting will feature ground breaking clinical trial results, cutting edge technology advancements, social networking events, and much more. Join over 1,900 of the worlds top gene and cell therapy professionals for four full days of educational offerings including plenary lectures given by Dr. David R. Liu and 2015 Japan Prize recipients, Dr. Alain Fischer, and Dr. Theodore Friedmann.
NIH Consensus Project on Clinical Trials in Chronic GVHD – evidence based revisions of 2005 recommendations and new developments, Tuesday, June 17, 2014 - Tuesday, June 17, 2014
Location: NCI at Shady Grove, Gaithersburg, MD
Description: The anticipated goal is to provide set of revised and improved diagnosis and staging recommendations, define the highest interest directions in research of cGVHD biology and biomarkers, and produce a firm proposal for a communal approach to the development of the reliable response criteria instruments. The meeting will also address methods to produce evidence on utilization and benefit of the new guidelines. At his time we will make this time also a concentrated effort to reexamine current knowledge of cGVHD biology in humans to inform future research.
Outcomes Database in Hematopoietic Cell Transplantation and Cellular Therapy for Autoimmune Diseases, Friday, April 19, 2013 - Saturday, April 20, 2013
Location: Froedtert and Medical College of Wisconsin, Milwaukee, WI
Description: The aim of this NIH workshop is to break the stalemate and facilitate interdisciplinary collaboration by creating functional clinical research teams on the national level who can then create a momentum for progress in this area of substantial unmet need and high promise. The CIBMTR infrastructure, which is currently cancer-focused, can be easily adapted to collect AID-specific data